BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 29776344)

  • 1. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
    Kawakami T; Tsushima T; Omae K; Ogawa H; Shirasu H; Kito Y; Yoshida Y; Hamauchi S; Todaka A; Machida N; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
    BMC Cancer; 2018 May; 18(1):573. PubMed ID: 29776344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: A retrospective analysis.
    Chen B; Deng M; Yang C; Dragomir MP; Zhao L; Bai K; Xi M; Hu Y; Zhu Y; Li Q
    Radiother Oncol; 2021 May; 158():191-199. PubMed ID: 33667583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303.
    Tsushima T; Mizusawa J; Sudo K; Honma Y; Kato K; Igaki H; Tsubosa Y; Shinoda M; Nakamura K; Fukuda H; Kitagawa Y;
    Medicine (Baltimore); 2016 May; 95(20):e3699. PubMed ID: 27196482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
    Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
    BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.
    Sugawara K; Yagi K; Okumura Y; Nishida M; Aikou S; Yamashita H; Yamashita H; Seto Y
    Int J Clin Oncol; 2020 Apr; 25(4):552-560. PubMed ID: 31828451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
    Dai H; Shao YW; Tong X; Wu X; Pang J; Feng A; Yang Z
    Cancer Med; 2020 Mar; 9(5):1628-1637. PubMed ID: 31851786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.
    Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma.
    Wang WT; Guo CQ; Cui GH; Zhao S
    World J Gastroenterol; 2019 Oct; 25(37):5604-5618. PubMed ID: 31602161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer.
    Wu SX; Li XY; Xu HY; Xu QN; Luo HS; Du ZS; Huang HC; Wu ZY
    Sci Rep; 2017 Dec; 7(1):16870. PubMed ID: 29203855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophageal fistula after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal squamous cell carcinoma.
    Pao TH; Chen YY; Chang WL; Chang JS; Chiang NJ; Lin CY; Lai WW; Tseng YL; Yen YT; Chung TJ; Lin FC
    PLoS One; 2021; 16(5):e0251811. PubMed ID: 33989365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Zhou XL; Wang WW; Zhu WG; Yu CH; Tao GZ; Wu QQ; Song YQ; Pan P; Tong YS
    Mol Carcinog; 2016 Dec; 55(12):2095-2105. PubMed ID: 26756568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study.
    Li W; Chen P; Zhang N; Song T; Wu S
    Oncologist; 2019 Apr; 24(4):461-e136. PubMed ID: 30850562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
    Chen M; Shen M; Lin Y; Liu P; Liu X; Li X; Li A; Yang R; Ni W; Zhou X; Zhang L; Xu B; Lin J; Chen J; Tian Y
    Radiat Oncol; 2018 Aug; 13(1):150. PubMed ID: 30111361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.
    Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D
    Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303).
    Shinoda M; Ando N; Kato K; Ishikura S; Kato H; Tsubosa Y; Minashi K; Okabe H; Kimura Y; Kawano T; Kosugi S; Toh Y; Nakamura K; Fukuda H;
    Cancer Sci; 2015 Apr; 106(4):407-12. PubMed ID: 25640628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy.
    Liw PX; Wen YW; Tsai CY; Chang HK; Tseng CK; Hung TM; Chao YK
    J Thorac Cardiovasc Surg; 2018 May; 155(5):2233-2242.e2. PubMed ID: 29397973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy.
    Okamoto H; Fujishima F; Kamei T; Nakamura Y; Ozawa Y; Miyata G; Nakano T; Katsura K; Abe S; Taniyama Y; Sakurai T; Teshima J; Hikage M; Sasano H; Ohuchi N
    BMC Cancer; 2015 Mar; 15():208. PubMed ID: 25880782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303).
    Okuno T; Wakabayashi M; Kato K; Shinoda M; Katayama H; Igaki H; Tsubosa Y; Kojima T; Okabe H; Kimura Y; Kawano T; Kosugi S; Toh Y; Kato H; Nakamura K; Fukuda H; Ishikura S; Ando N; Kitagawa Y;
    Int J Clin Oncol; 2017 Dec; 22(6):1042-1049. PubMed ID: 28717855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.